Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding

• Published in: The American journal of managed care Vol. 23; no. 4 Suppl; pp. S67 - S80
• Main Authors: Milling, Jr, Truman J, Frontera, Jennifer
• Format: Journal Article
• Language: English
• Published: United States 01.04.2017
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants - adverse effects; Anticoagulants - therapeutic use; Brain Ischemia - drug therapy; Female; Health administration; Hemorrhage - chemically induced; Humans; Male; Middle Aged; Stroke - chemically induced; Thrombosis - drug therapy; United States
• ISSN: 1088-0224; 1936-2692

Thrombosis is a leading cause of morbidity and mortality in the United States. Arterial and venous thromboses are implicated in the pathogenesis of major disorders, including myocardial infarction, ischemic stroke, and venous thromboembolism. Over the past decade, direct oral anticoagulants (DOACs) (eg, direct thrombin inhibitor and factor Xa [FXa] inhibitors) have been adopted as alternatives to warfarin due to their clinical advantages and efficacy for the treatment of thrombosis. As with all anticoagulants, treatment with DOACs is associated with a risk of major bleeding, including life-threatening gastrointestinal bleeds and intracranial hemorrhages (ICHs). In turn, the burden of bleeding associated with DOAC treatment is itself associated with substantial healthcare costs that are amplified by an increased risk of thromboembolic events and mortality following major bleeding events, especially in patients with ICHs. Given the rapid adoption of the DOACs and projected usage in the large patient population affected by thromboembolic conditions, clinicians are increasingly likely to encounter patients with major bleeding events due to DOAC therapy. Unlike warfarin, effective strategies to manage these bleeds are limited. There is an unmet need for reversal agents for use in the management of patients who receive FXa inhibitors and experience life-threatening bleeding or need emergency surgery. Andexanet alfa and ciraparantag are being evaluated as potential antidotes for both direct and indirect FXa inhibitors.